May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Effect of Latanoprost and Timolol on the Histopathology of the Human Conjunctiva
Author Affiliations & Notes
  • J. Lampel
    Department of Ophthalmology, University of Erlangen-Nürnberg, Erlangen, Germany
  • U. Schlötzer-Schrehardt
    Department of Ophthalmology, University of Erlangen-Nürnberg, Erlangen, Germany
  • A. G. Boehm
    Department of Ophthalmology, University of Dresden, Dresden, Germany
  • C. Rummelt
    Department of Ophthalmology, University of Erlangen-Nürnberg, Erlangen, Germany
  • F. E. Kruse
    Department of Ophthalmology, University of Erlangen-Nürnberg, Erlangen, Germany
  • L. E. Pillunat
    Department of Ophthalmology, University of Dresden, Dresden, Germany
  • Footnotes
    Commercial Relationships J. Lampel, None; U. Schlötzer-Schrehardt, None; A.G. Boehm, None; C. Rummelt, None; F.E. Kruse, None; L.E. Pillunat, None.
  • Footnotes
    Support SFB 539
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1550. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Lampel, U. Schlötzer-Schrehardt, A. G. Boehm, C. Rummelt, F. E. Kruse, L. E. Pillunat; Effect of Latanoprost and Timolol on the Histopathology of the Human Conjunctiva. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1550.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To determine the effect of the anti-glaucoma medications timolol and latanoprost on extracellular matrix organisation and expression of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the human conjunctiva.

Methods:: After informed consent, conjunctival biopsies were obtained at the inferior fornix during routine cataract surgery from 20 patients with primary open-angle glaucoma, who had received a monotherapy either with 0.5% timolol (mean age 75±7 years) or latanoprost (mean age 74±10 years) for 15-21 months and from 10 cataract patients without glaucoma (mean age 76±6 years) serving as controls. Specimens were investigated by light microscopy, quantitative transmission electron microscopy using an automated image-processing system, and immunohistochemistry using antibodies against MMP-1, MMP-3, TIMP-2, TIMP-3, and CD68.

Results:: The area occupied by collagen fibers was significantly decreased in latanoprost-treated conjunctival specimens as compared to timolol-treated eyes (31.8% versus 36.6%; p<0.01), but was not significantly different from controls (33.5%). The amount of amorphous material, probably representing proteoglycans, was increased in both treated groups as compared to controls (30.9%; p<0.001), but the difference was less pronounced in latanoprost-treated specimens (38.1%) as compared to timolol-treated eyes (43.3%; p<0.001). Approximately 30-40% of the area measured appeared as optically clear spaces in control eyes, with a significant reduction in both treated groups; this reduction was significantly less in latanoprost-treated specimens (19.0%) compared with timolol-treated eyes (13.4%; p<0.001). A marked upregulation of MMP-1 and MMP-3 protein and moderately increased staining for TIMP-2 and TIMP-3 was found in epithelial cells and subepithelial stromal cells of latanoprost-treated conjunctival tissue, whereas a moderate infiltration with macrophages and inflammatory cells was observed in timolol-treated specimens.

Conclusions:: Compared with timolol-treated eyes, latanoprost-treated conjunctival specimens showed a less dense stromal matrix and less pronounced inflammatory infiltration. The upregulation of MMP-1 and MMP-3 in latanoprost-treated eyes might explain the reduction of extracellular matrix accumulation in the conjunctival stroma. Therefore, latanoprost therapy might have a more favorable effect on the outcome of glaucoma filtering surgery.

Keywords: conjunctiva • microscopy: electron microscopy • pathobiology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×